Intra-Cellular Therapies v. Aurobindo: Lumateperone Patent Consolidation

Case Overview

The Parties

The Patents at Issue

Three U.S. patents are asserted in this litigation, forming the core of ITCI’s defensive perimeter around lumateperone:

• • US12128043B2 (Application No. US18/602981)
• • US12122792B2 (Application No. US18/240951)
• • US12090155B2 (Application No. US18/494754)

All three patents cover proprietary aspects of lumateperone’s formulation, composition, or related pharmaceutical technology. Notably, all carry high application numbers indicating relatively recent USPTO prosecution activity, suggesting ITCI has been actively expanding and refreshing its patent portfolio around CAPLYTA® concurrent with the generic threat.

The Accused Product

The accused product is lumateperone capsules, 42 mg — Aurobindo’s proposed generic equivalent to CAPLYTA®. Under the Hatch-Waxman framework, Aurobindo’s ANDA filing with a Paragraph IV certification constitutes a technical act of infringement, enabling ITCI to bring suit before any generic product reaches the market.

Legal Representation

ITCI was represented by Walsh Pizzi O’Reilly Falanga LLP, with attorneys Liza M. Walsh, Katelyn O’Reilly, and Lauren Ruth Malakoff appearing on record. Walsh Pizzi is a recognized New Jersey litigation firm with established pharmaceutical patent litigation experience. No defendant counsel was identified in the available case record for this specific action.

Litigation Timeline & Procedural History

The timeline of this case reflects a deliberate, wave-based litigation strategy by ITCI:

• • March 27–28, 2024: ITCI filed the foundational action against Aurobindo (3:24-cv-04264) and six additional ANDA filers — Alkem, Dr. Reddy’s Laboratories, Hetero, MSN Laboratories, Sandoz, and Zydus — within a 24-hour window across seven separate civil actions in the District of New Jersey.
• • August 29, 2024: ITCI filed a second wave of related civil actions (3:24-cv-08845 through 3:24-cv-08856) against the same seven defendants, likely asserting newly issued patents including those at issue in this case.
• • November 1, 2024: The present action (3:24-cv-10235) was filed against Aurobindo specifically, incorporating the three newly identified patents.
• • January 10, 2025: The case closed through consolidation with the primary Aurobindo action (3:24-cv-04264) within just 70 days of filing.

The 70-day duration is procedurally unremarkable in the consolidation context — its speed reflects efficient docket management rather than expedited merits resolution. The District of New Jersey is a preferred venue for Hatch-Waxman litigation due to its experienced judiciary and established pharmaceutical patent precedent.

The Verdict & Legal Analysis

Outcome

Case No. 3:24-cv-10235 was closed on January 10, 2025, with the basis of termination recorded as Case Consolidated. The action was merged into the broader consolidated proceeding anchored by Civil Action No. 3:24-cv-04264. No merits determination, damages award, or injunctive relief ruling was issued within this specific docket. The case’s closure reflects procedural efficiency rather than a substantive legal outcome.

Verdict Cause Analysis

The underlying cause of action is patent infringement under the Hatch-Waxman Act (35 U.S.C. § 271(e)(2)). ITCI’s infringement theory follows the standard Paragraph IV pathway: Aurobindo’s ANDA submission seeking FDA approval for a generic lumateperone product constitutes statutory infringement of the listed Orange Book patents.

The three asserted patents (US12128043B2, US12122792B2, US12090155B2) appear to have been listed or listable in the FDA Orange Book following issuance, prompting the second and third waves of litigation as new patents issued. This rolling assertion strategy — filing new suits as new patents issue — is a recognized and effective method for extending the Hatch-Waxman 30-month stay framework and maintaining market exclusivity.

Consolidation into the primary action ensures all three patent families are litigated on a unified schedule, preventing duplicative discovery, inconsistent claim constructions, and judicial inefficiency.

Legal Significance

Several legally significant elements emerge from this procedural architecture:

• • Multi-Patent, Multi-Defendant Coordination: ITCI’s simultaneous assertion against seven generic filers across overlapping patent families demonstrates how branded pharmaceutical companies can use coordinated Hatch-Waxman litigation to maximize litigation leverage and delay generic entry across the entire competitive field, not just one challenger.
• • Portfolio Freshness Strategy: The high application numbers on all three asserted patents (US18/602981; US18/240951; US18/494754) indicate these are continuation or related applications filed in 2023–2024, well into CAPLYTA®’s commercial lifecycle. This reflects active patent prosecution timed to generic ANDA filings — a strategy increasingly scrutinized but presently lawful under existing USPTO and court doctrine.
• • Consolidation as Docket Management: Courts in the District of New Jersey routinely consolidate related Hatch-Waxman actions for pretrial purposes. Consolidation preserves judicial resources while allowing plaintiffs to maintain separate dockets for procedural purposes if needed. For practitioners, understanding when consolidation is ordered versus when cases proceed independently is critical to managing litigation timelines.

Industry & Competitive Implications

The lumateperone patent litigation reflects broader dynamics reshaping the CNS pharmaceutical patent landscape. CAPLYTA® generated substantial commercial revenue following its FDA approvals for bipolar depression (2021) and schizophrenia, making its patent estate a high-value target for generic manufacturers seeking early market entry.

ITCI’s decision to assert patents against all major ANDA filers simultaneously — including Alkem, Dr. Reddy’s, Hetero, MSN, Sandoz, and Zydus — signals a total-defense posture characteristic of brand companies facing multi-filer generic challenges to blockbuster or near-blockbuster assets. This approach maximizes 30-month stay protection and forces each generic challenger to independently develop invalidity and non-infringement positions.

For the generic pharmaceutical industry, cases like this reinforce the challenge of entering markets protected by aggressively managed continuation patent portfolios. The ability of brand companies to file new Hatch-Waxman suits on continuation patents issued after the original ANDA filing creates compounding litigation exposure for generic manufacturers.

Licensing and settlement patterns in multi-defendant Hatch-Waxman cases often produce staggered authorized generic entry dates, with earlier-filing ANDA challengers potentially negotiating preferred launch windows. The consolidated docket structure here may ultimately facilitate or complicate such negotiations, depending on how the substantive proceedings develop.